The nucleotide sequences of the SARS-CoV-2 variants circulated in the Siberian Federal District in the 2020–2022 period were obtained by next-generation sequencing (NGS) in the WHO National Influenza Centre (Research Institute of Influenza) and the Federal Research Center of Fundamental and Translational Medicine [16 (link)], and most of them were deposited in the GISAID database. The selection of samples for sequencing was based on obtaining from several healthcare institutions located in different regions of the Siberian Federal District.
The complete genome NGS sequencing was performed using the Illumina MiSeq platform and the associated reagent kits (Illumina), according to the manufacturer’s methodology (Illumina, Inc. Worldwide Headquarters: 5200 Illumina Way, San Diego, CA 92122, USA). RNA was extracted using the QIAamp Viral RNA Mini Kit (Qiagen, Hilden, Germany). Whole-genome amplification was performed using the ARTIC primer set [18 ]. DNA libraries were prepared using a Nextera DNA Flex Library Prep kit (Illumina, San Diego, CA, USA). Sequencing of the DNA libraries was conducted on a MiSeq genome sequencer (Illumina) with a reagent kit, version 3 (600-cycle). The consensus sequences were generated using Bowtie 2 software [19 (link)].
The complete genome NGS sequencing was performed using the Illumina MiSeq platform and the associated reagent kits (Illumina), according to the manufacturer’s methodology (Illumina, Inc. Worldwide Headquarters: 5200 Illumina Way, San Diego, CA 92122, USA). RNA was extracted using the QIAamp Viral RNA Mini Kit (Qiagen, Hilden, Germany). Whole-genome amplification was performed using the ARTIC primer set [18 ]. DNA libraries were prepared using a Nextera DNA Flex Library Prep kit (Illumina, San Diego, CA, USA). Sequencing of the DNA libraries was conducted on a MiSeq genome sequencer (Illumina) with a reagent kit, version 3 (600-cycle). The consensus sequences were generated using Bowtie 2 software [19 (link)].
Free full text: Click here
